Showing results (1261-1270 of 1,611) with videos related to

Sort By:
Pageof 162
JAMA Oncology|December 13, 2019
The Need for Combined Assessment of Multiple Outcomes in Noninferiority Trials in OncologyIsmail Jatoi, Mitchell H Gail
JAMA Oncology|September 24, 2020
Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysisSmith Giri, Alyssa Grimshaw, Susan Bal, et al.
JAMA Oncology|October 1, 2020
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical TrialThomas Yau, Yoon-Koo Kang, Tae-You Kim, et al.
JAMA Oncology|October 1, 2020
Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical TrialAna Oaknin, Anna V Tinker, Lucy Gilbert, et al.
JAMA Oncology|March 28, 2020
Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate CancerRobert T Dess, Yilun Sun, William C Jackson, et al.
JAMA Oncology|July 29, 2021
Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Non-Small Cell Lung Cancer: The NRG-LU001 Phase 2 Randomized Clinical TrialHeath Skinner, Chen Hu, Theodoros Tsakiridis, et al.
JAMA Oncology|June 23, 2022
Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast CancerPaolo Tarantino, Qingchun Jin, Nabihah Tayob, et al.
JAMA Oncology|December 22, 2022
Effect of Oral β-Glucan on Antibody Response to Ganglioside Vaccine in Patients With High-Risk Neuroblastoma: A Phase 2 Randomized Clinical TrialIrene Y Cheung, Audrey Mauguen, Shakeel Modak, et al.
JAMA Oncology|April 14, 2022
Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic VariantsYukihide Momozawa, Rumi Sasai, Yoshiaki Usui, et al.
JAMA Oncology|September 23, 2016
Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh ScoreAndrew X Zhu, Ari David Baron, Peter Malfertheiner, et al.
Pageof 162